Yescarta
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Phil Taylor
Breyanzi, Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, lymphoma, Oncology, regulatory approval, Yescarta
0 Comment
ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma
Phil Taylor
CAR-T therapies, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta
0 Comment
ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma
Phil Taylor
Breyanzi, Bristol-Myers Squibb, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta
0 Comment
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC
Phil Taylor
AstraZeneca, CAR-T therapies, China, Gilead Sciences, HutchMed, immuno-oncology, lung cancer, Non-small cell lung cancer, Oncology, Orpathys, savolitinib, Yescarta
0 Comment
R&D/ Views & Analysis/ Views and analysis
Casting aside CRISPR scissors and making a point with base editors
mike.hammerton@pharmaphorum.com
CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta
0 Comment
Market Access/ News/ News/ News/ News/ Oncology/ Patients
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma
Phil Taylor
CAR T, Gilead Sciences, NHS, non-Hodgkin lymphoma, Oncology, Scotland, Yescarta
0 Comment
R&D/ Views & Analysis/ Views and analysis
Will cell and gene therapies disrupt reimbursement?
Dominic Tyer
cell and gene therapy, cell therapy, Deep Dive: Disruptive Technologies, gene therapy, Kymriah, Luxturna, PhRMA, Yescarta
0 Comment